Sydney-based EMVision Medical Devices reached the recruitment target for Stage 3 of its multi-site clinical trial, involving 30 haemorrhagic stroke patients.

The achievement highlighted the positive engagement at the investigational sites and the implementation of recruitment-accelerating initiatives.

The Stage 3 cohort includes a substantial number of ischaemic stroke participants, which aims to bolster EMVision's AI algorithm for neurodiagnostic capabilities.

Stage 3 results are expected to be reported during the second half of 2024.

The company has also submitted its pre-submission package to the US Food and Drug Administration, which is currently under review.